BridgeBio reports FDA Priority Review for oral infigratinib in achondroplasia
Published in Drugs development & discovery.
Publication date: October 6, 2026.
BridgeBio announced that the FDA accepted its application for oral infigratinib for children with achondroplasia and granted Priority Review. The target action date is February 4, 2027.
Acceptance for review is a regulatory milestone, not marketing approval. The treatment remains investigational for this indication; the target date does not guarantee an approval decision.
Source: BridgeBio company release distributed by GlobeNewswire, October 6, 2026.